Description

Product Description

EA-230 (CAS 503844-09-5) is a novel synthetic oligopeptide originally derived from lysates of beta-human chorionic gonadotropin (β-hCG). This peptide has attracted significant research interest due to its unique ability to modulate inflammatory responses, especially in the context of systemic inflammatory diseases and sepsis.

Background and Origin

Human chorionic gonadotropin (hCG) is a hormone secreted during pregnancy, playing roles in maternal-fetal tolerance, immunomodulation, and tissue adaptation. Researchers observed that lysates of β-hCG contained peptide fragments with profound immune-regulatory activity. EA-230 represents a synthetic analog of these functional fragments, specifically engineered to retain the beneficial anti-inflammatory effects without hormonal activity.

Pharmacological Relevance

EA-230 has been shown in multiple preclinical studies to reduce systemic inflammation, protect vascular function, and improve survival in models of sepsis. Unlike conventional anti-inflammatory drugs, EA-230 exerts broad-spectrum immunomodulation without fully suppressing the immune response, making it highly valuable for conditions where controlled dampening of inflammation is essential.

Research Applications

1. Sepsis Research – EA-230 has demonstrated protective effects in septic models, reducing cytokine storm and stabilizing hemodynamics.

2. Systemic Inflammation – It offers therapeutic potential in diseases characterized by excessive immune activation.

3. Organ Protection – Research suggests EA-230 can protect the kidneys, liver, and cardiovascular system from inflammatory injury.

4. Immunology Studies – It serves as a model peptide to explore the connection between reproductive hormones and immune regulation.

Through its unique pharmacological profile, EA-230 continues to be a promising research peptide in translational medicine and immunotherapy studies.

Product Specifications

Extended Specification Notes

• High Purity Assurance: HPLC analysis ensures consistency for reproducible research results.

• Storage and Stability: Stability under cold storage makes EA-230 reliable for long-term research projects.

• Application Spectrum: Particularly useful in sepsis models, but also expanding into autoimmune and organ-protection studies.

Mechanism of Action

EA-230’s mechanism centers on its ability to modulate immune and inflammatory pathways:

1. Cytokine Modulation

   • EA-230 reduces levels of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.

   • Simultaneously, it preserves or enhances anti-inflammatory cytokines like IL-10.

2. Vascular Protection

   • In sepsis, endothelial barrier dysfunction leads to fluid leakage and organ failure. EA-230 protects vascular integrity by stabilizing endothelial junctions and reducing permeability.

3. Immune Balance

   • Rather than complete immunosuppression, EA-230 induces a balanced immune response, which is crucial in sepsis research where fighting infection must continue while preventing excessive inflammation.

4. Interaction with Reproductive Hormone Pathways

   • As a derivative of β-hCG lysates, EA-230 demonstrates the biological link between reproductive hormones and immune regulation. This cross-disciplinary mechanism provides insights into pregnancy-associated immune tolerance.

5. Multi-Organ Protection

   • Preclinical studies show protective effects in kidney injury, liver dysfunction, and cardiovascular collapse, common in severe systemic inflammation.

EA-230 thus acts as a broad-spectrum immunomodulator, making it a versatile tool for translational immunological research.

Side Effects

Preclinical Safety Profile

• Low Toxicity: Animal studies report no major toxicological findings at therapeutic doses.

• Minimal Hormonal Activity: EA-230, while derived from β-hCG fragments, does not exhibit hormonal side effects such as endocrine disruption.

Potential Risks in Research Use

• Immune Interference: As an immunomodulatory peptide, improper dosing may lead to excessive suppression of inflammation, increasing vulnerability to infections.

• Allergic Reactions: As with other synthetic peptides, there is a theoretical risk of hypersensitivity.

• Hemodynamic Variability: Some models report transient effects on blood pressure and vascular tone.

Future Clinical Considerations

Further research is required to assess EA-230’s long-term safety, especially in human clinical contexts such as chronic inflammatory diseases or critical care.

Disclaimer

All information is provided for research and laboratory purposes only. EA-230 is not approved for human use, medical treatment, or diagnostic applications. Handling should follow laboratory safety protocols.

Keywords

EA-230 peptide, CAS 503844-09-5, synthetic oligopeptide, anti-inflammatory peptide, β-hCG derived peptide, sepsis research peptide, immunomodulatory oligopeptide, laboratory research peptide, vascular protection peptide.

Shipping Guarantee

We provide comprehensive global logistics services for research customers:

• Customs-Cleared & Tax-Inclusive: All products are shipped with full customs clearance and tax included, without requiring customers to provide complicated import documents.

• Full Compensation: In case of damage or loss during transportation, we provide 100% compensation to ensure your research is not interrupted.

• Efficient Delivery: Multiple international courier options are available, with trackable shipping information for secure and timely delivery.

Transaction Guarantee

We support a wide range of secure and flexible payment methods:

• T/T Bank Transfer

• PayPal

• Cryptocurrency payments (USDT, BTC, ETH, etc.)

• Additional payment options available upon request.

With strict transaction safeguards, we ensure your procurement experience is safe, transparent, and convenient.